v3.26.1
DESCRIPTION OF BUSINESS (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jul. 10, 2026
Apr. 03, 2025
May 10, 2024
Apr. 30, 2025
Jun. 30, 2025
Jun. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
DESCRIPTION OF BUSINESS                
Accumulated deficit             $ 652,711 $ 546,371
Cash, cash equivalents and marketable securities             $ 460,700  
Shares issued   9,935,419            
Share price   $ 20.13            
Gross proceeds       $ 200,000        
Proceeds from issuance of common stock       187,100   $ 187,362    
Underwriting discounts and commissions       12,000        
Offering expenses       $ 900        
Sevasemten program | Disposed of by sale                
DESCRIPTION OF BUSINESS                
Annual net sales milestone payment $ 300,000              
Annual net sales threshold amount 550,000              
Aggregate potential consideration 2,650,000              
Common Stock                
DESCRIPTION OF BUSINESS                
Shares issued         9,935,419      
Subsequent event | Sevasemten program | Disposed of by sale                
DESCRIPTION OF BUSINESS                
Consideration 1,550,000              
Additional contingent consideration 1,100,000              
Proceeds from the Sevasemten Sale received 1,550,000              
Subsequent event | Sevasemten program | Disposed of by sale | Approval For Becker Muscular Dystrophy, Adult And Adolescent Populations                
DESCRIPTION OF BUSINESS                
Payment on marketing approval 200,000              
Subsequent event | Sevasemten program | Disposed of by sale | Approval For Becker Muscular Dystrophy, Adult Populations                
DESCRIPTION OF BUSINESS                
Payment on marketing approval 100,000              
Subsequent event | Sevasemten program | Disposed of by sale | Approval For Duchenne Muscular Dystrophy                
DESCRIPTION OF BUSINESS                
Payment on marketing approval $ 600,000              
At-the-market program | Common Stock | Maximum                
DESCRIPTION OF BUSINESS                
Maximum potential aggregate sales proceeds, sales agreement     $ 175,000